The role of SH3BP2 in the pathophysiology of cherubism

Orphanet Journal of Rare Diseases

Volumn 7, Issue SUPPL. 1, 2012, Pages

  Reichenberger, Ernst J ^a   Levine, Michael A ^b   Olsen, Bjorn R ^c   Papadaki, Maria E ^d   Lietman, Steven A ^e  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; CALCINEURIN; NFATC1 PROTEIN, MOUSE; SH3BP2 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADAPTIVE IMMUNITY; AUTOINFLAMMATORY DISEASE; B LYMPHOCYTE; CONFERENCE PAPER; FIBROUS DYSPLASIA; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INNATE IMMUNITY; INTRACELLULAR SIGNALING; JAW; LYMPH NODE; MACROPHAGE; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INTERACTION; SH3BP2 GENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; T LYMPHOCYTE; UPREGULATION; ANIMAL; AUTOIMMUNE DISEASE; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PHOSPHORYLATION; REVIEW; TRANSCRIPTION INITIATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; AUTOIMMUNE DISEASES; BONE RESORPTION; CALCINEURIN; CHERUBISM; DISEASE MODELS, ANIMAL; GERM-LINE MUTATION; HUMANS; INFLAMMATION; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVATION;

EID: 84861363561     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-S1-S5     Document Type: Conference Paper

References (101)

1. Familial multilocular cystic disease of the jaws. Jones WA, American Journal of Cancer 1933 17 946 950
2. Cherubism - familial fibrous dysplasia of the jaws. Jones WA, Gerrie J, Pritchard J, J Bone Joint Surg Br 1950 32-B 334 347 14778852
3. Cherubism: Best Clinical Practice Orphanet. Papadaki ME, Lietman SA, Levine MA, Olsen BR, Kaban LB, Reichenberger EJ, Orphanet Journal of Rare Diseases 2012 7 Suppl 1 6
4. Cherubism-hereditary fibrous dysplasia of the jaws. I. Genetic considerations. Anderson DE, McClendon JL, Oral Surgery Oral Medicine Oral Pathology 1962 15 5 16
5. Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature. Von Wowern N, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000 90 765 772 10.1067/moe.2000.108438 11113824
6. The gene for cherubism maps to chromosome 4p16. Tiziani V, Reichenberger E, Buzzo CL, Niazi S, Fukai N, Stiller M, Peters H, Salzano FM, Raposo do Amaral CM, Olsen BR, Am J Hum Genet 1999 65 158 166 10.1086/302456 10364528 (Pubitemid 30470460)
7. The gene for cherubism maps to chromosome 4p16.3. Mangion J, Rahman N, Edkins S, Barfoot R, Nguyen T, Sigurdsson A, Townend JV, Fitzpatrick DR, Flanagan AM, Stratton MR, American Journal of Human Genetics 1999 65 151 157 10.1086/302454 10364527 (Pubitemid 30470459)
8. The primary structure and genomic organization of five novel transcripts located close to the Huntington's disease gene on human chromosome 4p16.3. Hadano S, Ishida Y, Ikeda JE, DNA Res 1998 5 177 186 10.1093/dnares/5.3.177 9734812 (Pubitemid 128670179)
9. Genotype-phenotype correlations and clinical diagnostic criteria in wolf-hirschhorn syndrome. Zollino M, DS C, Zampino G, Mastroiacovo P, Wright TJ, Sorge G, Selicorni A, Tenconi R, Zappala A, Battaglia A, Di Rocco M, Palka G, Pallotta R, Altherr MR, Neri G, Am J Med Genet 2000 94 254 261 10.1002/1096-8628(20000918)94:3<254::AID-AJMG13>3.0.CO;2-7 10995514
10. Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer. Bell SM, Shaw M, Jou YS, Myers RM, Knowles MA, Genomics 1997 44 163 170 10.1006/geno.1997.4849 9299232 (Pubitemid 27415540)
11. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Ueki Y, Tiziani V, Santanna C, et al. Nat Genet 2001 28 125 126 10.1038/88832 11381256 (Pubitemid 32538054)
12. Identification of a ten-amino acid proline-rich SH3 binding site. Ren R, Mayer BJ, Cicchetti P, Baltimore D, Science 1993 259 1157 1161 10.1126/science.8438166 8438166 (Pubitemid 23085353)
13. The adapter 3BP2: how it plugs into leukocyte signaling. Deckert M, Rottapel R, Adv Exp Med Biol 2006 584 107 114 10.1007/0-387-34132-3-8 16802602
14. Recruitment of the actin-binding protein HIP-55 to the immunological synapse regulates T cell receptor signaling and endocytosis. Le Bras S, Foucault I, Foussat A, Brignone C, Acuto O, Deckert M, J Biol Chem 2004 279 15550 15560 10.1074/jbc.M312659200 14729663 (Pubitemid 38618956)
15. Abl-SH3 binding protein 2, 3BP2, interacts with CIN85 and HIP-55. Le Bras S, Moon C, Foucault I, Breittmayer JP, Deckert M, FEBS Lett 2007 581 967 974 10.1016/j.febslet.2007.01.084 17306257 (Pubitemid 46282729)
16. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation. Lietman SA, Kalinchinko N, Deng X, Kohanski R, Levine MA, Hum Mutat 2006 27 717 718 16786512
17. A new mutation in the SH3BP2 gene showing reduced penetrance in a family affected with cherubism. de Lange J, van Maarle MC, van den Akker HP, Redeker EJ, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007 103 378 381 10.1016/j.tripleo.2006.05.012 17321449
18. Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism. Lo B, Faiyaz-Ul-Haque M, Kennedy S, Aviv R, Tsui LC, Teebi AS, Am J Med Genet A 2003 121A 37 40 10.1002/ajmg.a.20226 12900899 (Pubitemid 37059339)
19. A novel mutation in the SH3BP2 gene causes cherubism: case report. Li CY, Yu SF, BMC Med Genet 2006 7 84 10.1186/1471-2350-7-84 17147794 (Pubitemid 46178682)
20. Novel mutations in the SH3BP2 gene associated with sporadic central giant cell lesions and cherubism. Carvalho VM, Perdigao PF, Amaral FR, de Souza PE, De Marco L, Gomez RS, Oral Dis 2009 15 106 110 10.1111/j.1601-0825.2008.01499.x 19017279.
21. A novel mutation of the SH3BP2 gene in an aggressive case of cherubism. Carvalho VM, Perdigao PF, Pimenta FJ, de Souza PE, Gomez RS, De Marco L, Oral Oncol 2008 44 153 155 10.1016/j.oraloncology.2007.01.012 17368082 (Pubitemid 351179659)
22. An extreme case of cherubism. Silva EC, de Souza PE, Barreto DC, Dias RP, Gomez RS, Br J Oral Maxillofac Surg 2002 40 45 48 10.1054/bjom.2001.0654 11883969 (Pubitemid 34257282)
23. Noonan-like/multiple giant cell lesion syndrome. Cohen MM Jr., Gorlin RJ, Am J Med Genet 1991 40 159 166 10.1002/ajmg.1320400208 1897569
24. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Tartaglia M, Kalidas K, Shaw A, et al. Am J Hum Genet 2002 70 1555 1563 10.1086/340847 11992261 (Pubitemid 34533902)
25. Noonan syndrome: clinical aspects and molecular pathogenesis. Tartaglia M, Zampino G, Gelb BD, Mol Syndromol 2010 1 2 26 10.1159/000276766 20648242
26. Giant cell lesions in noonan syndrome: case report and review of the literature. Bufalino A, Carrera M, Carlos R, Coletta RD, Head Neck Pathol 2010 4 174 177 10.1007/s12105-010-0178-2 20383758
27. Noonan-like syndrome mutations in PTPN11 in patients diagnosed with cherubism. Jafarov T, Ferimazova N, Reichenberger E, Clin Genet 2005 68 190 191 15996221 (Pubitemid 40990635)
28. Phenotypic and genotypic characterisation of Noonan-like/multiple giant cell lesion syndrome. Lee JS, Tartaglia M, Gelb BD, Fridrich K, Sachs S, Stratakis CA, Muenke M, Robey PG, Collins MT, Slavotinek A, J Med Genet 2005 42 11 10.1136/jmg.2004.024091 15689434
29. A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome. Sarkozy A, Obregon MG, Conti E, Esposito G, Mingarelli R, Pizzuti A, Dallapiccola B, Eur J Hum Genet 2004 12 1069 1072 10.1038/sj.ejhg.5201290 15470362 (Pubitemid 39600135)
30. SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. Beneteau C, Cave H, Moncla A, Dorison N, Munnich A, Verloes A, Leheup B, Eur J Hum Genet 2009 17 1216 1221 10.1038/ejhg.2009.44 19352411
31. SOS1: a new player in the Noonan-like/multiple giant cell lesion syndrome. Hanna N, Parfait B, Talaat IM, Vidaud M, Elsedfy HH, Clin Genet 2009 75 568 571 10.1111/j.1399-0004.2009.01149.x 19438935
32. Neurofibromatosis presenting with a cherubism phenotype. van Capelle CI, Hogeman PH, van der Sijs-Bos CJ, Heggelman BG, Idowu B, Slootweg PJ, Wittkampf AR, Flanagan AM, Eur J Pediatr 2007 166 905 909 10.1007/s00431-006-0334-6 17120035 (Pubitemid 47101340)
33. Unusual form of recurrent giant cell granuloma of the mandible and lower extremities in a patient with neurofibromatosis type 1. Ruggieri M, Pavone V, Polizzi A, Albanese S, Magro G, Merino M, Duray PH, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 87 67 72 10.1016/S1079-2104(99)70297-0 9927083
34. NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. De Luca A, Bottillo I, Sarkozy A, et al. Am J Hum Genet 2005 77 1092 1101 10.1086/498454 16380919 (Pubitemid 41698528)
35. Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. Bertola DR, Pereira AC, Passetti F, de Oliveira PS, Messiaen L, Gelb BD, Kim CA, Krieger JE, Am J Med Genet A 2005 136 242 245 15948193 (Pubitemid 40967088)
36. ASD: a bioinformatics resource on alternative splicing. Stamm S, Riethoven JJ, Le Texier V, Gopalakrishnan C, Kumanduri V, Tang Y, Barbosa-Morais NL, Thanaraj TA, Nucleic Acids Res 2006 34 46 55 10.1093/nar/gkj031 16381912
37. A concerted HIF-1/MT1-MMP signalling axis regulates the expression of the 3BP2 adaptor protein in hypoxic mesenchymal stromal cells. Proulx-Bonneau S, Guezguez A, Annabi B, PLoS One 2011 6 21511 10.1371/journal.pone.0021511 21738685
38. 3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation. de la Fuente MA, Kumar L, Lu B, Geha RS, Mol Cell Biol 2006 26 5214 5225 10.1128/MCB.00087-06 16809760 (Pubitemid 44036193)
39. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Foucault I, Le Bras S, Charvet C, Moon C, Altman A, Deckert M, Blood 2005 105 1106 1113 15345594 (Pubitemid 40170882)
40. The chaperone protein 14-3-3 interacts with 3BP2/SH3BP2 and regulates its adapter function. Foucault I, Liu YC, Bernard A, Deckert M, J Biol Chem 2003 278 7146 7153 10.1074/jbc.M209509200 12501243 (Pubitemid 36800713)
41. Regulation of NK cell-mediated cytotoxicity by the adaptor protein 3BP2. Jevremovic D, Billadeau DD, Schoon RA, Dick CJ, Leibson PJ, J Immunol 2001 166 7219 7228 11390470 (Pubitemid 32525595)
42. Adaptor protein 3BP2 is a potential ligand of Src homology 2 and 3 domains of Lyn protein-tyrosine kinase. Maeno K, Sada K, Kyo S, Miah SM, Kawauchi-Kamata K, Qu X, Shi Y, Yamamura H, J Biol Chem 2003 278 24912 24920 10.1074/jbc.M301201200 12709437 (Pubitemid 37548651)
43. Regulation of FcepsilonRI-mediated degranulation by an adaptor protein 3BP2 in rat basophilic leukemia RBL-2H3 cells. Sada K, Miah SM, Maeno K, Kyo S, Qu X, Yamamura H, Blood 2002 100 2138 2144 10.1182/blood-2001-12-0340 12200378 (Pubitemid 35001249)
44. Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. Deckert M, Tartare-Deckert S, Hernandez J, Rottapel R, Altman A, Immunity 1998 9 595 605 10.1016/S1074-7613(00)80657-3 9846481 (Pubitemid 28557588)
45. Vav3 regulates osteoclast function and bone mass. Faccio R, Teitelbaum SL, Fujikawa K, Chappel J, Zallone A, Tybulewicz VL, Ross FP, Swat W, Nat Med 2005 11 284 290 10.1038/nm1194 15711558 (Pubitemid 40460556)
46. Tyrosine phosphorylation of adaptor protein 3BP2 induces T cell receptor-mediated activation of transcription factor. Qu X, Kawauchi-Kamata K, Miah SM, Hatani T, Yamamura H, Sada K, Biochemistry 2005 44 3891 3898 10.1021/bi048353o 15751964 (Pubitemid 40358040)
47. Integrins, growth factors, and the osteoclast cytoskeleton. Zou W, Teitelbaum SL, Ann N Y Acad Sci 2010 1192 27 31 10.1111/j.1749-6632.2009.05245.x 20392214
48. Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones. Chiusaroli R, Sanjay A, Henriksen K, Engsig MT, Horne WC, Gu H, Baron R, Dev Biol 2003 261 537 547 10.1016/S0012-1606(03)00299-9 14499658 (Pubitemid 37108791)
49. The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway. Peruzzi G, Molfetta R, Gasparrini F, Vian L, Morrone S, Piccoli M, Frati L, Santoni A, Paolini R, J Immunol 2007 179 2089 2096 17675467
50. SHP-1 dephosphorylates 3BP2 and potentially downregulates 3BP2-mediated T cell antigen receptor signaling. Yu Z, Maoui M, Zhao ZJ, Li Y, Shen SH, FEBS J 2006 273 2195 2205 10.1111/j.1742-4658.2006.05233.x 16649996
51. The adaptor protein 3BP2 binds human CD244 and links this receptor to Vav signaling, ERK activation, and NK cell killing. Saborit-Villarroya I, Del Valle JM, Romero X, Esplugues E, Lauzurica P, Engel P, Martin M, J Immunol 2005 175 4226 4235 16177062 (Pubitemid 41361956)
52. Increased Myeloid Cell Responses to M-CSF and RANKL Cause Bone Loss and Inflammation in SH3BP2 "Cherubism" Mice. Ueki Y, Lin CY, Senoo M, et al. Cell 2007 128 71 83 10.1016/j.cell.2006.10.047 17218256 (Pubitemid 46048888)
53. 3BP2 Adapter protein is required for receptor activator of NFkappaB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells. GuezGuez A, Prod'homme V, Mouska X, Baudot A, Blin-Wakkach C, Rottapel R, Deckert M, J Biol Chem 2010 285 20952 20963 10.1074/jbc.M109.091124 20439986
54. The etiology of Wolf-Hirschhorn syndrome. Bergemann AD, Cole F, Hirschhorn K, Trends Genet 2005 21 188 195 10.1016/j.tig.2005.01.008 15734578 (Pubitemid 40269858)
55. Health supervision and anticipatory guidance of individuals with Wolf-Hirschhorn syndrome. Battaglia A, Carey JC, Am J Med Genet 1999 89 111 115 10.1002/(SICI)1096-8628(19990625)89:2<111::AID-AJMG9>3.0.CO;2-G 10559766 (Pubitemid 30033166)
56. Natural history of Wolf-Hirschhorn syndrome: experience with 15 cases. Battaglia A, Carey JC, Cederholm P, Viskochil DH, Brothman AR, Galasso C, Pediatrics 1999 103 830 836 10.1542/peds.103.4.830 10103318 (Pubitemid 29274487)
57. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Takayanagi H, Kim S, Koga T, et al. Dev Cell 2002 3 889 901 10.1016/S1534-5807(02)00369-6 12479813 (Pubitemid 35460788)
58. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T, J Biol Chem 2002 277 41147 41156 10.1074/jbc.M205063200 12171919 (Pubitemid 35215706)
59. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA, J Biol Chem 2004 279 13984 13992 10.1074/jbc.M213067200 14722106 (Pubitemid 38468932)
60. Parathyroid hormone reversibly suppresses the differentiation of osteoprogenitor cells into functional osteoblasts. Bellows CG, Ishida H, Aubin JE, Heersche JN, Endocrinology 1990 127 3111 3116 10.1210/endo-127-6-3111 2174346
61. Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. Komarova SV, Pereverzev A, Shum JW, Sims SM, Dixon SJ, Proc Natl Acad Sci U S A 2005 102 2643 2648 10.1073/pnas.0406874102 15695591 (Pubitemid 40279430)
62. Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. Uhlen P, Burch PM, Zito CI, Estrada M, Ehrlich BE, Bennett AM, Proc Natl Acad Sci U S A 2006 103 2160 2165 10.1073/pnas.0510876103 16461457 (Pubitemid 43271640)
63. Mechanistic insight into osteoclast differentiation in osteoimmunology. Takayanagi H, J Mol Med 2005 83 170 179 10.1007/s00109-004-0612-6 15776286 (Pubitemid 40487405)
64. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ, Nat Immunol 2003 4 557 564 10.1038/ni929 12740575 (Pubitemid 36701339)
65. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Koga T, Inui M, Inoue K, et al. Nature 2004 428 758 763 10.1038/nature02444 15085135 (Pubitemid 38508286)
66. SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Lietman SA, Yin L, Levine MA, Biochem Biophys Res Commun 2008 371 644 648 10.1016/j.bbrc.2008.04.080 18440306
67. SH3BP2 mutations potentiate osteoclastogenesis via PLCgamma. Lietman SA, Yin L, Levine MA, J Orthop Res 2010 28 1425 1430 10.1002/jor.21164 20872577
68. PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R, J Clin Invest 2006 116 2869 2879 10.1172/JCI28775 17053833 (Pubitemid 44684472)
69. Phospholipase C-gamma is required for agonist-induced Ca2+ entry. Patterson RL, van Rossum DB, Ford DL, Hurt KJ, Bae SS, Suh PG, Kurosaki T, Snyder SH, Gill DL, Cell 2002 111 529 541 10.1016/S0092-8674(02)01045-0 12437926 (Pubitemid 35356558)
70. Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other? Wilde JI, Watson SP, Cell Signal 2001 13 691 701 10.1016/S0898-6568(01)00191-7 11602179 (Pubitemid 32800818)
71. Structure, function, and control of phosphoinositide-specific phospholipase C. Rebecchi MJ, Pentyala SN, Physiol Rev 2000 80 1291 1335 11015615
72. Families of phosphoinositide-specific phospholipase C: structure and function. Katan M, Biochim Biophys Acta 1998 1436 5 17 9838022
73. Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling. Watanabe D, Hashimoto S, Ishiai M, Matsushita M, Baba Y, Kishimoto T, Kurosaki T, Tsukada S, J Biol Chem 2001 276 38595 38601 10.1074/jbc.M103675200 11507089
74. Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. Humphries LA, Dangelmaier C, Sommer K, Kipp K, Kato RM, Griffith N, Bakman I, Turk CW, Daniel JL, Rawlings DJ, J Biol Chem 2004 279 37651 37661 10.1074/jbc.M311985200 15184383 (Pubitemid 39195478)
75. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Kim YJ, Sekiya F, Poulin B, Bae YS, Rhee SG, Mol Cell Biol 2004 24 9986 9999 10.1128/MCB.24.22.9986-9999.2004 15509800 (Pubitemid 39458823)
76. Sensitization of epidermal growth factor-induced signaling by bradykinin is mediated by c-Src. Implications for a role of lipid microdomains. Hur EM, Park YS, Lee BD, Jang IH, Kim HS, Kim TD, Suh PG, Ryu SH, Kim KT, J Biol Chem 2004 279 5852 5860 14630916 (Pubitemid 38220617)
77. Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. Jongstra-Bilen J, Puig Cano A, Hasija M, Xiao H, Smith CI, Cybulsky MI, J Immunol 2008 181 288 298 18566394
78. Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function. Mukherjee PM, Wang CJ, Chen IP, Jafarov T, Olsen BR, Ueki Y, Reichenberger EJ, Am J Orthod Dentofacial Orthop 2010 138 140 e141-140 e111; discussion 140-141 10.1016/j.ajodo.2010.04.004 20691350
79. Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Chipman SD, Sweet HO, McBride DJ Jr., Davisson MT, Marks SC Jr., Shuldiner AR, Wenstrup RJ, Rowe DW, Shapiro JR, Proc Natl Acad Sci U S A 1993 90 1701 1705 10.1073/pnas.90.5.1701 8446583 (Pubitemid 23069924)
80. Introduction of a Phe377del mutation in ANK creates a mouse model for craniometaphyseal dysplasia. Chen IP, Wang CJ, Strecker S, Koczon-Jaremko B, Boskey A, Reichenberger EJ, J Bone Miner Res 2009 24 1206 1215 10.1359/jbmr.090218 19257826
81. 23. Zur Differentialdiagnose osteo-fibroser Kieferekrankungen. Adler CP, Harle F, Verhandlungen der Deutschen Gesellschaft fur Pathologie 1974 58 308 314 4533377
82. Null mutations in human and mouse orthologs frequently result in different phenotypes. Liao BY, Zhang J, Proc Natl Acad Sci U S A 2008 105 6987 6992 10.1073/pnas.0800387105 18458337 (Pubitemid 351754517)
83. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties. Wang CJ, Chen IP, Koczon-Jaremko B, Boskey AL, Ueki Y, Kuhn L, Reichenberger EJ, Bone 2010 46 1306 1315 10.1016/j.bone.2010.01.380 20117257
84. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. Kalajzic I, Kalajzic Z, Kaliterna M, Gronowicz G, Clark SH, Lichtler AC, Rowe D, J Bone Miner Res 2002 17 15 25 10.1359/jbmr.2002.17.1.15 11771662 (Pubitemid 33150992)
85. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR, Glimcher LH, J Clin Invest 2008 118 3775 3789 10.1172/JCI35711 18846253
86. Differential contribution of NFATc2 and NFATc1 to TNF-alpha gene expression in T cells. Kaminuma O, Kitamura F, Kitamura N, Hiroi T, Miyoshi H, Miyawaki A, Miyatake S, J Immunol 2008 180 319 326 18097033
87. The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response. Chen G, Dimitriou ID, La Rose J, Ilangumaran S, Yeh WC, Doody G, Turner M, Gommerman J, Rottapel R, Mol Cell Biol 2007 27 3109 3122 10.1128/MCB.01014-06 17283041 (Pubitemid 46581322)
88. Autoinflammatory bone disorders. Ferguson PJ, El-Shanti HI, Curr Opin Rheumatol 2007 19 492 498 10.1097/BOR.0b013e32825f5492 17762617 (Pubitemid 47344244)
89. The hereditary autoinflammatory syndromes. Chitkara P, Stojanov S, Kastner DL, Pediatr Infect Dis J 2007 26 353 354 10.1097/01.inf.0000258777. 86510.da 17414402 (Pubitemid 46596663)
90. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. McGonagle D, Aziz A, Dickie LJ, McDermott MF, Pediatr Res 2009 65 38R 45R 10.1203/PDR.0b013e31819dbd0a 19190531
91. A proposed classification of the immunological diseases. McGonagle D, McDermott MF, PLoS Med 2006 3 297 10.1371/journal.pmed.0030297 16942393 (Pubitemid 44338360)
92. Unexpected matrix diseases and novel therapeutic strategies. Nicolae C, Olsen BR, Cell Tissue Res 2010 339 155 165 10.1007/s00441-009-0874-y 19813027
93. TNF-mediated inflammatory disease. Bradley JR, J Pathol 2008 214 149 160 10.1002/path.2287 18161752 (Pubitemid 351160153)
94. Mechanism of inflammation in cherubism. Ueki Y, Mukai T, Yoshitaka T, In J Bone Miner Res 2010 25 Suppl 1 Available at [ http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx?aid=9553097c-08c8-4d7e-897a-6ed4927d0475 ] Accessed [12-24-2010]
95. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL, J Clin Invest 1997 100 1557 1565 10.1172/JCI119679 9294124 (Pubitemid 27425783)
96. Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis. Liu J, Wang S, Zhang P, Said-Al-Naief N, Michalek SM, Feng X, J Biol Chem 2009 284 12512 12523 10.1074/jbc.M809789200 19258321
97. LPS-induced inhibition of osteogenesis is TNF-alpha dependent in a murine tooth extraction model. Tomomatsu N, Aoki K, Alles N, Soysa NS, Hussain A, Nakachi H, Kita S, Shimokawa H, Ohya K, Amagasa T, J Bone Miner Res 2009 24 1770 1781 10.1359/jbmr.090410 19419299
98. Inhibition of osteoblastic cell differentiation by lipopolysaccharide extract from Porphyromonas gingivalis. Kadono H, Kido J, Kataoka M, Yamauchi N, Nagata T, Infect Immun 1999 67 2841 2846 10338489 (Pubitemid 29244698)
99. Molecular mechanisms of the inhibitory effect of lipopolysaccharide (LPS) on osteoblast differentiation. Bandow K, Maeda A, Kakimoto K, Kusuyama J, Shamoto M, Ohnishi T, Matsuguchi T, Biochem Biophys Res Commun 2010 402 755 761 10.1016/j.bbrc.2010.10.103 21036155
100. Toll-like receptor signaling. Akira S, J Biol Chem 2003 278 38105 38108 10.1074/jbc.R300028200 12893815 (Pubitemid 37221695)
101. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. Sato N, Takahashi N, Suda K, et al. J Exp Med 2004 200 601 611 10.1084/jem.20040689 15353553 (Pubitemid 39258309)